The U.S. government has bought an additional 650,000 doses of Eli Lilly’s coronavirus antibody treatment bamlanivimab (LY-CoV555).

The purchase agreement is for $812.5 million.

Bamlanivimab recently received emergency use authorization for the treatment of mild to moderate coronavirus patients who are at high risk for progressing to severe coronavirus symptoms and/or hospitalization.

The doses will be delivered through January 31, 2021. At least 350,000 of the additional doses will be delivered this month. This purchase brings the total doses purchased by the U.S. government to 950,000.

“Given the significant increase in COVID-19 cases and hospitalizations in the U.S., we are doing everything possible to quickly provide more bamlanivimab doses to Americans,” said David A. Ricks, Lilly’s chairman and CEO. “We are proud of our work to deploy significant manufacturing capacity and remain committed to enabling widespread and equitable access to bamlanivimab. The U.S. government’s effort to allocate bamlanivimab around the country is critical to ensuring it reaches patients who need it the most.”

Americans who get bamlanivimab would not have to pay anything out-of-pocket, but healthcare facilities may charge a fee for it to be administered.